

Efficacy, tolerability and quality of life – can these all be achieved for patients with mRCC?

Date:
Sunday 28 September 2014

Time:
18:00–20:00

Location:
Alicante Auditorium, IFEMA – Feria de Madrid, Madrid, Spain

Not intended for US Healthcare Professionals

This meeting is sponsored by GSK. GSK has been involved in selecting the faculty and in the creation of the agenda and the content. This meeting will have promotional content.



Agenda

18:00–18:05	Welcome and introduction	Bernard Escudier
18:05–18:25	Real-world experience: achieving efficacy beyond clinical trials	Nizar Tannir
18:25–18:45	Are we doing all we can to manage adverse events?	Bernard Escudier
18:45–19:05	Understanding the patient's perspective	David Cella
19:05–19:25	Panel Discussion	All
19:25–19:30	Closing remarks	Bernard Escudier

We are delighted to invite you to the GSK-sponsored satellite symposium:
Efficacy, tolerability and quality of life – can these all be achieved for patients with metastatic renal cell carcinoma (mRCC)?

Over the past decade a number of agents have been approved for the treatment of mRCC. The unique features of each agent are traditionally identified in the clinical trials leading to medicine registrations. However, we need to continue to study efficacy and safety in the real world and seek to understand the patient perspective with regard to quality of life, to fully understand these agents and inform our clinical decision making.

We have designed a stimulating symposium involving a panel of experts who will review the progress made in mRCC treatment, focusing on both clinical and real-world evidence. Through interactive presentations and discussions the experts will address the question of whether it is possible for mRCC patients to achieve efficacy, tolerability, as well as to maintain their quality of life. We are confident that the symposium will help you to optimise patient care in your own clinic.

Bernard Escudier
Meeting Chair,
Institut Gustave Roussy,
Villejuif, France



Bernard Escudier
Meeting Chair,
Institut Gustave Roussy,
Villejuif, France



Nizar Tannir
MD Anderson Cancer Center,
Houston, Texas, USA



David Cella
Feinberg School of Medicine,
Northwestern University,
Chicago, USA

